<?xml version="1.0" encoding="us-ascii"?>
<html><head><title>Johnson &amp; Johnson Clinical Trials in tranSMART Search</title>
<meta content="text/html; charset=us-ascii" http-equiv="Content-Type" /><link rel="stylesheet" type="text/css" href="../Theme/nav.css" /><link rel="stylesheet" type="text/css" href="../Theme/popupmenu.css" /><link rel="stylesheet" type="text/css" href="../Theme/lf.css" /><link rel="stylesheet" type="text/css" href="../LinksExt/d2hTarget.css" />
<script type="text/javascript">
//<![CDATA[



var _needIndentation = false;




//]]></script>

<script language="JavaScript" src="../linker.js" type="text/JavaScript"></script>

<script language="JavaScript" src="../special.js" type="text/JavaScript"></script>

<script language="JavaScript" src="../common.js" type="text/JavaScript"></script>

<meta name="Generator" content="ComponentOne Doc-To-Help v.2011.1.0.614" />
<meta name="D2HTheme" content="(Default) v.146" />
</head>
<body style="PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #535353; MARGIN: 7px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; OVERFLOW: hidden; PADDING-TOP: 0px" onload="d2hOnLoadToolbar(event);" relpart="../">
<script language="javascript" type="text/javascript">
//<![CDATA[



d2hTopicPreOpen();



d2hTrySyncTOC();







var prev = true;





var next = true;



if (typeof d2hInitMainThemeHandlers != "undefined")

    d2hInitMainThemeHandlers(prev, next);

d2hAdjustTopicBorders(document);    



if (typeof d2hLoadWindows != "undefined")

    d2hLoadWindows();

if (typeof d2hLoadNavUrls != "undefined")

    d2hLoadNavUrls();




//]]></script>

<div style="PADDING-BOTTOM: 0px; BACKGROUND-COLOR: white; MARGIN: 0px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; HEIGHT: 100%; OVERFLOW: auto; PADDING-TOP: 0px" id="D2HTopicOuterBody" class="d2h_outer_topic">
<div id="nsbanner" class="d2hNavigatorTopic">
<div style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" id="TitleRow" class="d2h_main_titlerow">
<div style="DISPLAY: none"><a id="D2HPreviousAnchor" href="trialsandstudiesindatasetexplorer.htm"></a><a id="D2HNextAnchor" href="resolveddefects.htm"></a></div></div>
<script language="javascript" type="text/javascript">
//<![CDATA[

if (typeof d2hProcessTopicNavForCSH != "undefined")

    d2hProcessTopicNavForCSH();


//]]></script>
</div>
<div style="PADDING-BOTTOM: 10px; PADDING-LEFT: 22px; PADDING-RIGHT: 10px; HEIGHT: 100%; PADDING-TOP: 5px" id="nstext" class="d2h_main_nstext" valign="bottom">
<div id="d2h_breadcrumbs" class="d2h_breadcrumbs"><span class="d2h_breadcrumbsLabel"><b><span style="COLOR: #000080">Release 
Notes</span></b>&#160;&#160;</span><a class="d2h_breadcrumbsNormal" href="transmartreleasenotes.htm">tranSMART Release Notes</a></div>
<h2><a name="_Toc242498269" id="_Toc242498269"></a><a name="_Toc297145016" id="_Toc297145016"></a><a name="_Toc251842385" id="_Toc251842385">Johnson &amp; Johnson Clinical Trials in tranSMART 
Search</a></h2>
<p style="PAGE-BREAK-AFTER: avoid" class="MsoNormal"><span style="COLOR: black">The following table shows the list of Johnson &amp;&#160; 
Johnson clinical trials that can be included in a tranSMART search 
result.</span></p>
<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" class="tranSMARTTable" border="1" cellspacing="0" cellpadding="0" width="583">
  <thead>
  <tr>
    <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" width="86">
      <p class="TableHeading0"><span style="COLOR: black; FONT-SIZE: 8pt">Trial</span></p></td>
    <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" width="314">
      <p class="TableHeading0"><span style="COLOR: black; FONT-SIZE: 8pt">Title</span></p></td>
    <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" width="183">
      <p class="TableHeading0"><span style="COLOR: black; FONT-SIZE: 8pt">Platform</span></p></td></tr></thead>
  <tbody>
  <tr style="PAGE-BREAK-INSIDE: avoid; HEIGHT: 28.35pt">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0168T37</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Randomized, Placebo-controlled, 
      Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in 
      Patients with Active Ulcerative Colitis.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0168T44</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase III, Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety 
      of Infliximab Induction Therapy Followed by Multiple Regimens of 
      Maintenance Infliximab Therapy in Subjects with Plaque-type 
      Psoriasis.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0168T48</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy 
      of Infliximab (REMICADE&#174;) in Subjects with Chronic Sarcoidosis with 
      Pulmonary Involvement.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">RBM</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0379T02</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase I, Double-blind, 
      Placebo-controlled Study Evaluating the Safety and Pharmacology of Single 
      Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 
      1275) in Subjects with Moderate to Severe Psoriasis 
Vulgaris.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">DNA</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0379T03</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase I, Double-blind, 
      Placebo-controlled Study Evaluating the Safety and Pharmacology of Single 
      Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 
      1275) in Subjects with Relapsing Forms of Multiple 
Sclerosis.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">DNA</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0379T07</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Multicenter, Randomized, Phase 2a 
      Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects 
      With Moderately to Severely Active Crohn&#8217;s Disease.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0524T03</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase 2, Multicenter, Randomized, 
      Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study 
      Evaluating the Efficacy and Safety Of CNTO 148 Administered Subcutaneously 
      in Symptomatic Subjects With Severe Persistent Asthma.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0743T10</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase 2, Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human 
      Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects 
      with Active Psoriatic Arthritis.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">RBM</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0743T12</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">A Phase 3, Multicenter, Randomized 
      Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to 
      Severe Plaque Psoriasis.</span></p></td>
    <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</span></p></td></tr>
  <tr style="PAGE-BREAK-INSIDE: avoid">
    <td style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="86">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">C0743X01`</span></p></td>
    <td style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" valign="top" width="314">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Detection of Mediators of Sarcoidosis 
      Skin Lesions.</span></p></td>
    <td style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" valign="top" width="183">
      <p style="MARGIN-TOP: 6pt" class="MsoNormal"><span style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array, RBM</span></p></td></tr></tbody></table></div></div></body></html>
